Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVM CEL-SCI	$9.45 +15.5%	$3.59	$1.98 ▼ $39.30	$50.28M	0.3	380,418 shs	521,184 shs
IBIO iBio	$0.66 -3.1%	$0.80	$0.64 ▼ $6.89	$10.89M	0.94	1.45 million shs	371,327 shs
JSPR Jasper Therapeutics	$2.88 -0.7%	$4.68	$2.27 ▼ $26.05	$43.56M	2.69	1.36 million shs	268,314 shs
PEPG PepGen	$1.32 -3.6%	$1.37	$0.88 ▼ $10.15	$44.83M	1.19	202,195 shs	64,081 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVM CEL-SCI	+15.53%	+15.24%	+275.00%	+25.50%	-72.25%
IBIO iBio	-3.09%	-10.11%	-10.95%	-34.75%	-67.85%
JSPR Jasper Therapeutics	-0.69%	-8.57%	-57.77%	-46.77%	-84.42%
PEPG PepGen	-3.65%	-8.97%	+9.09%	-16.98%	-88.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVM CEL-SCI	1.2111 of 5 stars	0.0	2.0	4.3	1.7	0.6
IBIO iBio	1.3151 of 5 stars	3.5	0.0	0.6	0.0	0.6
JSPR Jasper Therapeutics	2.7047 of 5 stars	4.3	2.0	1.1	1.7	0.6
PEPG PepGen	2.6609 of 5 stars	3.2	2.0	2.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVM CEL-SCI	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	658.73% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$29.75	932.99% Upside
PEPG PepGen	2.33	Hold	$7.67	480.81% Upside

Current Analyst Ratings Breakdown

Latest IBIO, PEPG, JSPR, and CVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
IBIO iBio	$375K	29.03	N/A	N/A	$1.41 per share	0.47
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$3.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVM CEL-SCI	-$26.92M	-$12.61	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)
PEPG PepGen	-$89.98M	-$3.13	N/A	N/A	N/A	N/A	-81.26%	-63.65%	8/14/2025 (Estimated)

Latest IBIO, PEPG, JSPR, and CVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PEPG PepGen	-$0.8150	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.28	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	PEPG PepGen	-$0.72	-$0.92	-$0.20	-$0.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVM CEL-SCI	0.66	1.07	1.09
IBIO iBio	0.05	1.76	1.76
JSPR Jasper Therapeutics	N/A	4.31	4.31
PEPG PepGen	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVM CEL-SCI	12.08%
IBIO iBio	7.90%
JSPR Jasper Therapeutics	79.85%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
CVM CEL-SCI	9.93%
IBIO iBio	0.58%
JSPR Jasper Therapeutics	4.60%
PEPG PepGen	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVM CEL-SCI	43	5.32 million	64.67 million	Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable
PEPG PepGen	30	32.72 million	31.02 million	Not Optionable

IBIO, PEPG, JSPR, and CVM Headlines

Recent News About These Companies

PEPGEN (PEPG) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Against PepGen and Encourages Investors to Contact the Firm

August 2 at 10:38 AM | globenewswire.com

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.

August 1 at 3:36 PM | globenewswire.com

Shareholders That Lost Money on PepGen Inc. (PEPG) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

August 1 at 12:13 PM | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

August 1 at 10:00 AM | globenewswire.com

PepGen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG

August 1 at 9:00 AM | prnewswire.com

PEPG DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages PepGen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 8 Deadline in Securities Class Action – PEPG

July 31 at 4:17 PM | globenewswire.com

Investors Who Lost Money on PepGen Inc. (PEPG) Should Contact Levi & Korsinsky About Pending Class Action - PEPG

July 31 at 4:08 PM | globenewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG

July 31 at 10:00 AM | prnewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 31 at 9:40 AM | prnewswire.com

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) Shareholders

July 31 at 8:45 AM | prnewswire.com

PEPG Deadline: PEPG Investors with Losses in Excess of $100K Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit

July 30 at 5:42 PM | prnewswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

July 30 at 5:41 PM | globenewswire.com

PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

July 30 at 4:25 PM | globenewswire.com

PepGen (NASDAQ:PEPG) Shares Down 3.5% - Here's Why

July 30 at 3:43 AM | americanbankingnews.com

PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 29, 2025 | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

July 29, 2025 | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

July 29, 2025 | prnewswire.com

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8,

July 28, 2025 | bakersfield.comB

Lost Money on PepGen Inc. (PEPG)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

July 28, 2025 | theglobeandmail.com

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.

July 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, PEPG, JSPR, and CVM Company Descriptions

CEL-SCI NYSE:CVM

$9.45 +1.27 (+15.53%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$9.29 -0.16 (-1.69%)

As of 08/1/2025 07:58 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

iBio NYSE:IBIO

$0.66 -0.02 (-3.09%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.61%)

As of 08/1/2025 07:58 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Jasper Therapeutics NASDAQ:JSPR

$2.88 -0.02 (-0.69%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.85 -0.03 (-1.01%)

As of 08/1/2025 07:50 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

PepGen NASDAQ:PEPG

$1.32 -0.05 (-3.65%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.32 -0.01 (-0.38%)

As of 08/1/2025 06:57 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time